Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2)

被引：0
|
作者：
Reig, Maria
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Llovet, Josep M.
Schelman, William R.
Liang, Kun
Wang, Chunxiao
Widau, Ryan C.
Abada, Paolo
Zhu, Andrew X.
机构：
[1] Hosp Clin Barcelona, Barcelona Clin Liver Canc Grp, Liver Unit, IDIBAPS,CIBEREHD, Barcelona, Spain
[2] Univ Med Mainz, Mainz, Germany
[3] Kindai Univ, Fac Med, Osaka, Japan
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
    Kudo, Masatoshi
    Galle, Peter R.
    Brandi, Giovanni
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Finn, Richard S.
    Llovet, Josep M.
    Assenat, Eric
    Merle, Philippe
    Chan, Stephen L.
    Palmer, Daniel H.
    Ikeda, Masafumi
    Yamashita, Tatsuya
    Vogel, Arndt
    Huang, Yi-Hsiang
    Abada, Paolo B.
    Yoshikawa, Reigetsu
    Shinozaki, Kenta
    Wang, Chunxiao
    Widau, Ryan C.
    Zhu, Andrew X.
    JHEP REPORTS, 2021, 3 (02)
  • [2] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Llovet, J. M.
    Finn, R. S.
    Kang, Y-K.
    Yen, C. J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Ohno, I.
    Daniele, B.
    Vogel, A.
    Yamashita, T.
    Hsu, C-H.
    Meyer, T.
    Widau, R.
    Schelman, W.
    Wang, C.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
    Kudo, M.
    Galle, P. R.
    Motomura, K.
    Assenat, E.
    Merle, P.
    Brandi, G.
    Daniele, B.
    Okusaka, T.
    Tomasek, J.
    Borg, C.
    Zagonel, V.
    Morimoto, M.
    Pracht, M.
    Finn, R. S.
    Llovet, J.
    Homma, G.
    Jen, M-H.
    Shinozaki, K.
    Yoshikawa, R.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 292 - 292
  • [4] Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
    Kudo, Masatoshi
    Finn, Richard S.
    Morimoto, Manabu
    Rau, Kun-Ming
    Ikeda, Masafumi
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep M.
    Daniele, Bruno
    Lim, Ho Yeong
    McIlwain, David W.
    Yoshikawa, Reigetsu
    Nakamura, Kenichi
    Liang, Kun
    Wang, Chunxiao
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    LIVER CANCER, 2021, 10 (05) : 451 - 460
  • [5] Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort
    Finn, R.
    De Toni, E.
    Yau, T. C. C.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A.
    SWISS MEDICAL WEEKLY, 2020, : 27S - 27S
  • [6] Ramucirumab As Second-Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies (REACH-2 and REACH)
    Llovet, Josep M.
    Kudo, Masatoshi
    Finn, Richard
    Galle, Peter R.
    Blanc, Jean-Frederic
    Okusaka, Takuji
    Chau, Ian
    Abada, Paolo B.
    Hsu, Yanzhi
    Zhu, Andrew X.
    HEPATOLOGY, 2018, 68 : 166A - 166A
  • [7] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
    Zhu, A. X.
    Finn, R. S.
    Galle, P. R.
    Llovet, J. M.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Cella, D.
    Girvan, A.
    Gable, J.
    Bowman, L.
    Hsu, Y.
    Abada, P. B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 208 - 208
  • [8] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
    Galle, Peter
    Kudo, Masatoshi
    Llovet, Josep M.
    Finn, Richard
    Karwal, Mark
    Denis, Pezet
    Kim, Tae-You
    Yang, Tsai-Sheng
    Zagonel, Vittorina
    Tomasek, Jiri
    Phelip, Jean-Marc
    Touchefeu, Yann
    Koh, Su-Jin
    Stirnimann, Guido
    Wang, Chunxiao
    Widau, Ryan
    Hsu, Yanzhi
    Abada, Paolo B.
    Zhu, Andrew
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E46 - E46
  • [9] PATIENT-REPORTED OUTCOMES (PROS) WITH RAMUCIRUMAB VERSUS PLACEBO IN CHINESE PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AND ELEVATED ALPHA-FETOPROTEIN FROM THE RANDOMIZED PHASE 3 REACH-2 STUDY
    Chen, X.
    Shao, G.
    Bai, Y.
    Gu, S.
    Gu, K.
    Zhang, Q.
    Zhang, W.
    Liu, J.
    Zhou, L.
    Qin, S.
    VALUE IN HEALTH, 2022, 25 (12) : S19 - S20
  • [10] Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
    Llovet, Josep M.
    Singal, Amit G.
    Villanueva, Augusto
    Finn, Richard S.
    Kudo, Masatoshi
    Galle, Peter R.
    Ikeda, Masafumi
    Callies, Sophie
    McGrath, Louise M.
    Wang, Chunxiao
    Abada, Paolo
    Widau, Ryan C.
    Gonzalez-Gugel, Elena
    Zhu, Andrew X.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2297 - 2305
12345